Larimar Therapeutics (LRMR)
Develops nomlabofusp to deliver frataxin in Friedreich's ataxia.
Something off on this page? Send us feedback.
Develops nomlabofusp, a subcutaneous recombinant fusion protein intended to deliver frataxin to mitochondria in Friedreich's ataxia. Operates as a U.S.-based clinical-stage biotech with one development segment and no approved commercial product in the context sources.
Built around nomlabofusp, a subcutaneous recombinant fusion protein intended to deliver frataxin to mitochondria in Friedreich's ataxia patients. The program came from Chondrial's CTI-1601 work and remains the named lead asset in Larimar's pipeline.
Runs as a U.S.-based clinical-stage biotechnology company with one reportable segment for clinical and preclinical product development. Pipeline materials describe a CPP intracellular delivery platform, but context sources identify no separate marketed product or named second clinical candidate.
Execution centers on regulatory development: FDA removed a partial clinical hold, later granted Breakthrough Therapy Designation, and Larimar submitted the first module of a rolling BLA. The business depends on nomlabofusp development and regulatory review rather than commercial product sales.
Company facts
Target rangeAs of Sep 22, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Aug 5, 2026 | Wedbush | Reiterate | Rating: —Target: $12 | Target: $11 |
| Jun 30, 2026 | Robert W. Baird | Target | Target: $7 | Target: $5 |
| Mar 3, 2026 | Wedbush | Reiterate | Rating: —Target: $22 | Target: $12 |
| Sep 30, 2025 | Robert W. Baird | Target | Target: — | Target: $7 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $156.3M · Total debt $5.0M · Total assets $165.3M · Shareholders' equity $127.4M
- Revenue
- $0
- Operating income
- −$34.4M
- Net income
- −$32.8M
No dividends on record.
| Institutions | ≈ 92.16% | 95.74M shares | |
|---|---|---|---|
| 171 holders · as of Jun 30, 2026 · largest filers plus last quarter's tail | |||
| Insiders | 1.40% | 1.46M shares | |
| 7 holders · as of Jul 8, 2026 | |||
| Other | ≈ 6.44% | 6.68M shares | |
| remainder | |||
103.88M company shares as of Sep 23, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
This quarter's institutional total failed a plausibility check; shown: the largest filers plus last quarter's remainder.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
Deerfield Management Company, L.P. (Series C)Institution | 34.28% | 35.61M | as of Jun 30, 2026 |
Blue Owl Capital Holdings LPInstitution | 8.82% | 9.16M | as of Jun 30, 2026 |
BlackRock, Inc.Institution | 5.47% | 5.68M | as of Jun 30, 2026 |
Defilade Capital Management, L.P.Institution | 3.53% | 3.67M | as of Jun 30, 2026 |
Driehaus Capital Management LLCInstitution | 3.05% | 3.16M | as of Jun 30, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Jul 6, 2026 | Thomas Edward Hamilton | director | +50,000 | $3.34 |
| Feb 27, 2026 | Jeffrey W. Sherman | director | +5,000 | $5.00 |
| Feb 27, 2026 | Frank E. Thomas | director | +5,000 | $5.00 |
| Feb 27, 2026 | Thomas Edward Hamilton | director | +100,000 | $5.00 |
| Feb 27, 2026 | James E. Flynn | director, 10 percent owner, other: * Director by Deputization | +5,000,000 | $5.00 |
- Biogen
Approved FA therapy anchor through Skyclarys
- PTC Therapeutics
Registration-stage FA small molecule vatiquinone
- Lexeo Therapeutics
FA cardiomyopathy gene therapy with LX2006
- Design Therapeutics
Frataxin-expression program with DT-216P2
- Solid Biosciences
Early FA dual-route gene therapy SGT-212
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Larimar Therapeutics | $3.74 | −1.97% | $396.8M | — | — | — | — |
| Biogen | $223.67 | −0.75% | $33.30B | 39.9 | 16.9 | 3.3 | +3.4% |
| PTC Therapeutics | $63.49 | −3.75% | $5.51B | — | 51.3 | 5.5 | +101.6% |
| Lexeo Therapeutics | $3.53 | −13.23% | $319.6M | — | — | — | — |
| Design Therapeutics | $12.34 | −6.23% | $821.9M | — | — | — | — |
| Solid Biosciences | $8.27 | −7.29% | $878.2M | — | — | — | — |
| Median | 39.9 | 34.1 | 4.4 | +52.5% |